department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Emtriva · pharmadog

pharmadog
drugs
Emtriva

drug

patient view →

emtricitabine

Marketedupdated 2mo ago

by $GILD GILEAD SCIENCES, INC.

Approved

community read0 votes

all catalysts(2)

approval · 2

EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE (EMTRICITABINE) — FDA approval

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE (EMTRICITABINE) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Emtriva

generic

emtricitabine

indication

Human Immunodeficiency Virus (HIV) Infections (AIDS)

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 6

drugEMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE12 co-mentions · 3 sources
drugEMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE12 co-mentions · 3 sources
tagApproval12 co-mentions · 3 sources
tagSmall Molecule6 co-mentions · 3 sources
drugtenofovir alafenamide4 co-mentions · 2 sources
drugTENOFOVIR DISOPROXIL FUMARATE2 co-mentions · 1 sources

Trials studying emtricitabine

phase3A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapyactive not recruitingn=307
phase3A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)recruitingn=4,580
phase1A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)not yet recruitingn=16
phase3Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressedactive not recruitingn=675
phase3Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treatedterminatedn=73
phase3Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)completedn=195
phase2Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvadacompletedn=35
—Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Preventionrecruitingn=3,000

more trials →